Article Text

Download PDFPDF
651 Exploring the prognostic relevance of ROMO 1 expression and its association with histological type and lymph node status in cervical cancer: a comprehensive retrospective immunohistochemical analysis
  1. Angel Yordanov1,
  2. Stoyan Kostov2,3,
  3. Yonka Ivanova3,
  4. Yavor Kornovski3,
  5. Stanislav Slavchev3,
  6. Ihsan Hasan4,
  7. Mariela Vasileva-Slaveva5,
  8. Velizar Shivarov2,
  9. Polina Dimitrova6,
  10. Konstantina Karakadieva1 and
  11. Eva Tsoneva7
  1. 1Department of Gynecologic Oncology, Medical University Pleven, Pleven, Bulgaria
  2. 2Research Institute, Medical University Pleven, Pleven, Bulgaria
  3. 3Department of Gynecology, Hospital ‘Saint Anna’, Medical University—’Prof. Dr. Paraskev Stoyanov’, Varna, Bulgaria
  4. 4Department of Obstetrics and Gynecology, University Hospital, Sofia, Bulgaria
  5. 5Department of Breast Surgery, Shterev Hospital, Sofia, Bulgaria
  6. 6Department of General and Clinical Pathology, Heart and Brain Center of Clinical Excellence, Pleven, Bulgaria
  7. 7Department of Reproductive Medicine, ‘Dr. Shterev’ Hospital, Sofia, Bulgaria


Introduction/Background Despite diligent efforts in primary and secondary prevention, cervical cancer (CC) persists as a prevalent malignancy among women, necessitating the exploration of novel prognostic and predictive factors for practical application. Existing literature suggests a correlation between the expression levels of Reactive Oxygen Species Modulator 1 (ROMO 1) and the disease stage. The objective of the retrospective study was to establish the potential association between the ROMO 1 expression levels and the histological type and the lymph node status in CC patients.

Methodology For each participant, a 3 µm-thick section from the corresponding formalin-fixed and paraffin-embedded tumor block underwent staining for ROMO1 (Clone OTI2C12, Mo, dilution 1:150, Abcam, UK). The immunohistochemical procedure employed the EnVision™ FLEX, High pH (DAKO) system and the AutostainerLink 48 technique (DAKO). The H score was utilized due to the absence of an established scoring system for ROMO 1.

Results This retrospective study, encompassing the years 2015–2020, encompasses a cohort of 150 CC patients who received treatment at the Department of Oncogynecology of Medical University Pleven (see table 1).

From the studies, no statistically significant difference was found in the expression of ROMO 1 in patients N0 and N1 (p=0.969), but when we analyzed the relationship with the histological types statistically significant difference was noted (p=0.002).

Conclusion ROMO1 expression was highest in SCC, followed by ASC and AC and there is no significant difference in expression levels according to lymph node status in CC patients.

Disclosures The authors have no relevant financial or non-financial interests to disclose.

Abstract 651 Table 1

Patient’s characteristics.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.